An exploratoly study to evaluate biomarkers in cell free DNA of "Sequential therapy from afatinib to osimertinib for EGFR mutant non small cell lung cancer: a multicenter prospective observational study (Gio Tag Japan)".

An exploratoly study to evaluate biomarkers in cell free DNA of "Sequential therapy from afatinib to osimertinib for EGFR mutant non small cell lung cancer: a multicenter prospective observational study (Gio Tag Japan)". - Biomarker study in cell free DNA of Gio-Tag Japan.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043235

Enrollment

Registered

2021-02-03

Start date

2020-12-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer(EGFR mutation positive)

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients enrolled in Gio-Tag Japan study

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
To evaluate the correlation between the presence or absence of compound mutations in cfDNA and the duration of treatment with sequential therapy from afatinib to osimertinib	—

Secondary

Measure	Time frame
1) To evaluate the correlation between the presence or absence of compound mutations in cfDNA at resistance to afatinib and the duration of afatinib treatment 2) To evaluate the correlation between the presence or absence of compound mutations in cfDNA before afatinib treatment and the duration of osimertinib treatment 3) To evaluate the correlation between the presence or absence of compound mutations in cfDNA and overall survival 4) To evaluate changes in compound mutations before afatinib and at resistance	—

Measure

Time frame

1) To evaluate the correlation between the presence or absence of compound mutations in cfDNA at resistance to afatinib and the duration of afatinib treatment 2) To evaluate the correlation between the presence or absence of compound mutations in cfDNA before afatinib treatment and the duration of osimertinib treatment 3) To evaluate the correlation between the presence or absence of compound mutations in cfDNA and overall survival 4) To evaluate changes in compound mutations before afatinib and at resistance

—

Countries

Japan

Contacts

Public ContactHideharu Kimura

Kanazawa University Hospital Respiratory Medicine

hkimura3625@staff.kanazawa-u.ac.jp076-265-2000

Outcome results